Ruthenium-based complex nanocarriers for cancer therapy.

Area of Science:

• Organometallic Chemistry
• Supramolecular Chemistry
• Drug Delivery Systems

Background:

• Ruthenium complexes are explored for anticancer properties.
• Developing stable and effective drug delivery systems is crucial for cancer therapy.
• Nucleoside-based ligands can influence the properties of metal complexes.

Purpose of the Study:

• To synthesize and characterize novel organometallic ruthenium complexes.
• To evaluate the self-aggregation behavior and formulation stability of these complexes.
• To assess the in vitro antiproliferative activity of the synthesized ruthenium complexes against cancer cells.

Main Methods:

• Synthesis of AziRu and its nucleoside-based derivatives (ToThyRu, HoThyRu, DoHuRu).
• Formulation of complexes in 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC) phospholipid vesicles.
• Investigation of self-aggregation using techniques to identify liposome and micelle formation.
• In vitro antiproliferative assays to determine cytotoxicity against cancer cell lines.

Main Results:

• Successful synthesis and stabilization of four ruthenium complexes in POPC formulations.
• Demonstrated self-aggregation into stable liposomes and, under certain conditions, elongated micelles.
• Formulations exhibited stability over extended periods (months).
• High in vitro antiproliferative activity was observed for the complexes.

Conclusions:

• The synthesized ruthenium complexes, particularly the AziRu derivatives, show promise as anticancer agents.
• The ability to form stable supramolecular structures like liposomes enhances their potential as drug delivery vectors.
• These findings open new avenues for designing transition metal-based supramolecular systems for cancer therapy.